Wuzhou Zhongheng paid $52 million for a 10% stake in Israel's Oramed Pharma and China rights to its two oral diabetes treatments; Hadasit Bio Holdings, a medical transfer technology company located in Jerusalem, announced a $2 million investment from unspecified Chinese investors; Provectus Biopharma signed an LOI with Boehringer Ingelheim (China) for China development of Provectus' lead cancer molecule; Desano Pharma of Shanghai struck a deal with ViiV Healthcare to make the API for GlaxoSmithKline's new HIV drug; a new official China study shows that 25% of China's adult population suffer from hypertension and almost 10% have diabetes. Colorcon, a privately held US CRO/CMO excipient maker, opened a lab in Beijing; and Zhejiang Kanglaite Group will start a large US Phase III trial of its lead drug, Kanglaite, a TCM-derived medication, in patients with pancreatic cancer.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
